RUBINSTEIN JULIE sold $929K of ADPT

RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $26.06 ($25.23–$27.45, $0.93M total) across 5 trades over 2026-10-30 to 2026-11-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RUBINSTEIN JULIE
Published Nov 4, 2026, 12:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Bearish
high confidence
Mentioned
$ADPT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTBearishLow
01

Why it matters

The disclosed sale is the first public report of this transaction, making it a primary source of new information.

02

Market read

A senior executive's $0.93 M stock sale may prompt short‑term downside sentiment, but overall market impact is limited.

03

What to watch

Potential upcoming data releases or clinical milestones that may offset any short‑term pressure.

Relevance 4/10Novelty 4/10Timing: post‑market filing

Background

Form 4 filings are mandatory disclosures of insider transactions, providing transparency on insider activity.

Company-level read

Ticker impact

$ADPTBearishHigh confidence
Context

President and COO Julie Rubinstein sold 35,643 shares of Adaptive Biotechnologies for $928,891 via a 10b5‑1 plan, disclosed in a Form 4 filing.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A senior officer sold nearly $1 M of stock, indicating possible personal liquidity need or reduced confidence, which typically triggers short‑term downside bias.

Market effects

Minimal; biotech sector not broadly affected by a single insider sale.

None

None

Counterpoint

The sale could be routine liquidity management and not reflect company fundamentals.

Key entities

  • Adaptive Biotechnologies Corp

    Biotech firm focused on immune profiling and diagnostics.

  • Julie Rubinstein

    President and COO of Adaptive Biotechnologies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.